In the current study, we sought to determine whether the expression levels of alternative splicing isoforms at the FMR1 locus were significantly different both in premutation carriers who did and did not develop symptoms of FXTAS over time compared to non-carrier healthy controls. The gene discussed is FMR1; the disease is fragile X-associated tremor/ataxia syndrome.